Biora Therapeutics, Inc. Common Stock
BIOR
BIOR was delisted on the 10th of December, 2024.
51 hedge funds and large institutions have $59.2M invested in Biora Therapeutics, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 14 increasing their positions, 9 reducing their positions, and 14 closing their positions.
113% more call options, than puts
Call options by funds: $6.38M | Put options by funds: $2.99M
56% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 9
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less funds holding
Funds holding: 53 → 51 (-2)
14% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 14
42% less capital invested
Capital invested by funds: $101M → $59.2M (-$42.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Neuberger Berman Group
New York
|
+$2.97M |
| 2 |
Millennium Management
New York
|
+$2.4M |
| 3 |
VF
Virtu Financial
New York
|
+$564K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$558K |
| 5 |
State Street
Boston,
Massachusetts
|
+$510K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$1.93M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$900K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$887K |
| 4 |
D.E. Shaw & Co
New York
|
-$550K |
| 5 |
Wolverine Trading
Chicago,
Illinois
|
-$257K |
BIOR Hedge Fund Activity: Q1 2022 in Review
51 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Biora Therapeutics, Inc. Common Stock (BIOR) for Q1 2022, worth a combined $59.2M — down 42% from $101M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of BIOR and 12 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 14 added.
The largest buyer was Neuberger Berman Group, adding an estimated $2.97M. The largest seller was Two Sigma Investments, exiting entirely with an estimated $1.93M sold.
- 51 institutional investors held Biora Therapeutics, Inc. Common Stock (BIOR) as of Q1 2022, down from 53 in Q4 2021.
- Funds reported $59.2M of Biora Therapeutics, Inc. Common Stock stock for Q1 2022, down 42% quarter-over-quarter.
- 12 funds opened new Biora Therapeutics, Inc. Common Stock positions in Q1 2022 and 14 closed out, a net change of -2 holders.
- The largest Biora Therapeutics, Inc. Common Stock buyer in Q1 2022 was Neuberger Berman Group, an estimated $2.97M added.
- The largest Biora Therapeutics, Inc. Common Stock seller in Q1 2022 was Two Sigma Investments, an estimated $1.93M sold.
Based on aggregated 13F filings for Q1 2022.